OmRx Oncology begins phase 2 trial of oral PD-L1 inhibitor OX-4224 in patients with non-small cell lung cancer: San Diego Saturday, May 10, 2025, 12:00 Hrs [IST] OmRx Oncology, or ...

BOTHELL, Wash., May 09, 2025 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a clinical stage biopharmaceutical company focused on developing small molecules to restore neuronal health and ...

Vesper Bio achieves enrolment milestone in Phase Ib/IIa trial of lead candidate VES001 for frontotemporal dementia Phase Ib/IIa trial is to evaluate the efficacy of VES001 in asymptomatic patients ...

Learn more about whether BioCryst Pharmaceuticals, Inc. or Roivant Sciences Ltd. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Enrollment on track in Phase 2 pivotal portion of PYNNACLE clinical trial evaluating rezatapopt as monotherapy in patients with TP53 Y220C and KRAS wild-type advanced solid tumorsInterim analysis from ...

On track for mid-year initiations of planned Phase 2 studies in ulcerative colitis ("UC") and rheumatoid arthritis ("RA"), providing for 7+ proof-of-concept readouts ...

More patients in the linerixibat group had clinically meaningful itch improvement (WI-NRS =3-point reduction) with 56% versus 43% in the placebo group at week 24 (treatment difference 13% [95% CI ...

Alterity Therapeutics Limited’s ATHE share price has surged by 8.51%, which has investors questioning if this is right time to sell.

Net loss for the three months ended March 31, 2025, totaled $11.1 million, with non-cash share-based compensation expense of ...

Initiated dose expansion in Phase 1 CARDINAL trial of TERN-701 in 2L+ CML Additional safety and efficacy data including ...

WTX-124 Phase 1/1b clinical trial on track for data readouts and interactions with the FDA in the second half of the year - - First patient dosed in the Phase 1b/2 clinical trial of WTX-330, seeking ...

Simulations suggest that an extraordinary jump in temperatures seen in 2023 and 2024 could simply be natural variability, ...